The Drugs.com Monthly Update Podcast

The Drugs.com Monthly Update Podcast

Drugs.com
Country USA
Language EN
Episodes 16
Latest 06.11.2026

The Drugs.com Monthly Update Podcast provides monthly summaries of developments in pharmaceuticals and healthcare. Each episode covers new drug approvals, updated indications, safety alerts, and other important medical news. It is produced by Drugs.com for listeners who want to stay informed about medication and health-related updates.

Episodes

  • Drugs.com - Monthly Update October 2026
    Drugs.com - Monthly Update October 2026 06.11.2026 6m
    In this October 2026 edition of the Drugs.com Monthly Update Podcast, learn about the FDA's latest approvals, including Lucamzi, Brytly, and Ryzumvi for eye conditions, Hibsago for chronic hepatitis B, Hovilpri for refractory HSV, Weltruza for schizophrenia, and Ilumya for active psoriatic arthritis.Lucamzi (ranibizumab-blrz): A newly approved biosimilar to Lucentis for the treatment of macular degeneration and other retinal conditions. Hibsago (bepirovirsen): An innovative targeted treatment for chronic hepatitis B virus infection, capable of achieving a functional cure in some patients. Bryt...
  • Drugs.com - Monthly Update September 2026
    Drugs.com - Monthly Update September 2026 03.10.2026 8m
    This September 2026 Drugs.com Monthly Update covers several new FDA approvals that provide novel treatment options and expand therapeutic possibilities.Zanvastro (zilganersen): A GFAP-directed antisense oligonucleotide for the treatment of Alexander disease in pediatric and adult patients. Juvmo (tavapadon): A selective D1/D5 receptor partial agonist for the treatment of Parkinson's disease. Isembyld (apitegromab-mstn): A myostatin-targeted treatment for children and adults with spinal muscular atrophy receiving SMN2-targeted therapy. Onswik (insulin efsitora alfa-gobe): A once-weekly basal in...
  • Drugs.com - Monthly Update August 2026
    Drugs.com - Monthly Update August 2026 03.09.2026 6m
    In our August 2026 episode of Drugs.com Monthly Update, we review the latest round of FDA approvals bringing new therapeutic strategies to patients and prescribers.mFLUSIVA (influenza vaccine, mRNA): A new mRNA-based seasonal flu vaccine approved for the prevention of influenza disease in adults 50 years of age and older.Orzeyful (oveporexton): An innovative orexin receptor 2 agonist approved for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adult patients.Genglycos (pariglasgene brecaparvovec-opnr): A novel gene therapy for adults and pediatric patients 8 years and older w...
  • Drugs.com - Monthly Update July 2026
    Drugs.com - Monthly Update July 2026 02.08.2026 7m
    This July 2026 Drugs.com Monthly Update covers several new FDA approvals that provide novel treatment options and expand therapeutic possibilities.Gwyn Lo (ethinyl estradiol and norelgestromin): A new once-weekly transdermal patch providing low-dose estrogen and progestin for pregnancy prevention.Lytenava (bevacizumab-vikg): The first FDA-approved ophthalmic formulation of bevacizumab for patients with wet age-related macular degeneration.Simtriyo (centanafadine): A novel triple reuptake inhibitor approved for the treatment of ADHD in adults and pediatric patients 6 years and older.Jideytro (z...
  • Drugs.com - Monthly Update June 2026
    Drugs.com - Monthly Update June 2026 03.07.2026 3m
    This month, we're exploring advances across multiple therapeutic areas. We cover Lumvoa for thyroid eye disease, Utebzi for complicated urinary tract infections, and Tregzi for blood cancers.Lumvoa (veligrotug-vvze): Approved for thyroid eye disease, Lumvoa is an IGF-1R inhibitor that offers significant improvements in TED symptoms, with notable early effectiveness.Utebzi (tebipenem pivoxil): The first oral carbapenem approved in the U.S., providing a new option for treating complicated urinary tract infections, demonstrating efficacy comparable to intravenous options.Tregzi (Orca-T or allogen...
  • Drugs.com - Monthly Update May 2026
    Drugs.com - Monthly Update May 2026 03.06.2026 8m
    In this May 2026 Monthly Update edition, we cover several new FDA approvals and a major prescription-to-OTC switch expanding therapeutic options.Veppanu (vepdegestrant): The first PROTAC (PROteolysis TArgeting Chimera) therapy to be approved for ESR1-mutated, ER+/HER2- advanced or metastatic breast cancer based on strong progression-free survival clinical data.Trimbow (beclomethasone dipropionate/formoterol fumarate/glycopyrrolate): A triple-combination inhalation aerosol approved for the long-term maintenance treatment of adult asthma.Xocova (ensitrelvir): The first oral antiviral tablet indi...
  • Drugs.com - Monthly Update April 2026
    Drugs.com - Monthly Update April 2026 02.05.2026 5m
    In this April 2026 Monthly Update edition, we highlight several FDA approvals that introduce first-of-their-kind therapies and improve access to existing treatments.Foundayo (orforglipron): A first-of-its-kind small-molecule oral GLP-1 receptor agonist for chronic weight management without strict food or water requirements.Otarmeni (lunsotogene parvec-cwha): An innovative gene therapy for pediatric and adult patients with OTOF-related genetic hearing loss.Idvynso (doravirine and islatravir): A new once-daily, two-drug single-tablet regimen for adults with HIV-1 who are virologically suppressed...
  • Drugs.com - Monthly Update March 2026
    Drugs.com - Monthly Update March 2026 02.04.2026 4m
    In this March 2026 edition of Drugs.com Monthly Update Podcast, learn about the FDA's latest approvals, including Wegovy HD for obesity, Icotyde for plaque psoriasis, Sotyktu for psoriatic arthritis, and Awiqli for type 2 diabetes. Wegovy HD (semaglutide): A new high-dose option for adults managing obesity, showing significant weight loss in clinical trials.Icotyde (icotrokinra): The first oral IL-23 blocker approved to treat moderate-to-severe plaque psoriasis, providing a new oral treatment choice.Sotyktu (deucravacitinib): An oral TYK2 inhibitor now approved for treating active psoriatic ar...
  • Drugs.com - Monthly Update February 2026
    Drugs.com - Monthly Update February 2026 01.03.2026 5m
    In this February 2026 edition of Drugs.com Monthly Update Podcast, learn about new options in weight management, type 2 diabetes, and lung cancer. Discover Eli Lilly's Zepbound KwikPen for simplified dosing in obesity management, the upcoming launch of the oral Ozempic pill for diabetes by Novo Nordisk, IBSA Pharma’s oral film formulation of sildenafil for erectile dysfunction called Vybrique, and the monthly Rybrevant Faspro injection for advanced NSCLC.Zepbound KwikPen (tirzepatide): A new multidose Zepbound pen supplying 4 fixed weekly doses in one pen Ozempic pill (semaglutide): Discover t...
  • Drugs.com - Monthly Update January 2026
    Drugs.com - Monthly Update January 2026 01.02.2026 5m
    In our latest episode, we cover the latest approval of Darzalex Faspro for multiple myeloma, age-related near vision loss, and a rare genetic disorder affecting children. We also discuss an extension to the use of Nexplanon, a long-acting birth control, and a simpler transition for those moving from injected to inhaled insulin.Darzalex Faspro (daratumumab and hyaluronidase-fihj) a new approval for use in combination with standard treatments for adults with newly diagnosed multiple myeloma.Yuvezzi (carbachol and brimonidine tartrate), a novel combination eye drop for presbyopia.Zycubo (copper h...
  • Drugs.com - Monthly Update December 2025
    Drugs.com - Monthly Update December 2025 01.01.2026 5m
    This month, discover the Wegovy tablet, the first oral GLP-1 weight loss medication to be approved, Myqorzo's long-awaited treatment for obstructive hypertrophic cardiomyopathy, and several other exciting new FDA approvals. Explore these key stories and more in our December 2025 round-up.Wegovy (semaglutide) tablet, the first oral GLP-1 for weight loss, with significant efficacy in patient trials.Myqorzo (aficamten), a long-awaited and major addition to obstructive hypertrophic cardiomyopathy treatment that improves exercise capacity.Exdensur (depemokimab-ulaa), a new long-term, add-on treatme...
  • Drugs.com - Monthly Update November 2025
    Drugs.com - Monthly Update November 2025 01.12.2025 4m
    In this episode, we explore key FDA approvals from November 2025, including treatments like Keytruda Qlex for bladder cancer, Epkinly for follicular lymphoma, and the long-acting Eylea HD for macular edema. Discover what these developments mean for patients and professionals alike.Keytruda (pembrolizumab), approved in combination with Padcev as neoadjuvant treatment for adults with muscle-invasive bladder cancer ineligible for cisplatin-containing chemotherapy, demonstrating a 60% reduction in event-free survival events.Epkinly (epcoritamab-bysp) plus rituximab and lenalidomide, approved for a...
  • Drugs.com - Monthly Update October 2025
    Drugs.com - Monthly Update October 2025 01.11.2025 4m
    This month’s update dives into significant FDA approvals affecting key therapeutic areas. Discover groundbreaking treatments like Novo Nordisk’s Rybelsus for cardiovascular risk reduction in diabetes, and innovative solutions like Gazyva for lupus nephritis. Tune in to learn how these advancements could impact patient management and outcomes.Rybelsus (semaglutide): Exploring its new role in cardiovascular risk reduction for adults with type 2 diabetes.Zoryve (roflumilast): A breakthrough steroid-free topical treatment for eczema in young children.Gazyva (obinutuzumab): Approved for lupus nephr...
  • Drugs.com - Monthly Update September 2025
    Drugs.com - Monthly Update September 2025 01.10.2025 5m
    Discover the latest in pharmaceutical advancements with our September 2025 roundup. We're covering newly approved treatments like Rhapsido for chronic spontaneous urticaria, Palsonify for acromegaly, and Inluriyo for ESR1-mutated breast cancer. Learn about groundbreaking therapies, their impacts on patient care, and what these mean for healthcare professionals and patients alike.Rhapsido (remibrutinib) for the management of difficult chronic spontaneous urticaria in adults still experiencing symptoms despite antihistamine therapy.Palsonify (paltusotine) introduces a groundbreaking once-daily o...
  • Drugs.com - Monthly Update August 2025
    Drugs.com - Monthly Update August 2025 01.09.2025 4m
    August 2025 brought significant advances in therapies for conditions ranging from metabolic liver disease to pediatric migraine prevention and beyond. Tune in as we delve into key FDA approvals like Novo Nordisk's Wegovy for MASH, Tonmya for fibromyalgia, and Ajovy's pediatric migraine approval, and explore their implications in clinical practice.Wegovy (semaglutide) for metabolic liver disease: Now indicated for metabolic dysfunction-associated steatohepatitis (MASH) in adults, offering a new treatment pathway for this progressive liver condition.Tonmya (cyclobenzaprine) for fibromyalgia: A p...
  • Drugs.com - Monthly Update July 2025
    Drugs.com - Monthly Update July 2025 01.08.2025 4m
    This month we explore groundbreaking FDA approvals including Ekterly for hereditary angioedema, Anzupgo for chronic hand eczema, and the new dosing regimen of Kisunla for Alzheimer’s. We’ll discuss the mechanisms, patient impacts, and data that drive these advancements.Ekterly (sebetralstat), approved as an oral on-demand treatment for hereditary angioedema (HAE) attacks in patients 12 years and older, providing symptom relief in just 1.6 hours compared to 6.7 hours with placebo.Anzupgo (delgocitinib), the first steroid-free topical treatment approved in the U.S. for moderate to severe chronic...
  • Drugs.com - Monthly Update June 2025
    Drugs.com - Monthly Update June 2025 01.07.2025 5m
    This is the June 2025 edition of the Drugs.com Monthly Update. We cover five significant FDA approvals that are transforming patient care across multiple therapeutic areas.Dupixent (dupilumab), newly approved for treating bullous pemphigoid in adults—a painful autoimmune skin disorder primarily affecting patients over 65.Mavyret (glecaprevir/pibrentasvir) for acute hepatitis C virus treatment in children as young as 3 years old.Yeztugo (lenacapavir), a groundbreaking twice-yearly injectable HIV prevention therapy offering a 99.9% effectiveness rate in clinical trials.Enflonsia (clesrovimab-cfo...

Popular in

The podcast also appears in the podcast charts of these countries.